Copyright Reports & Markets. All rights reserved.

Global Immune Check Point Inhibitors Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Immune Check Point Inhibitors Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 CLTA-4 Inhibitors
      • 1.4.3 PD-1 & PD-L1 Inhibitor
    • 1.5 Market by Application
      • 1.5.1 Global Immune Check Point Inhibitors Market Share by Application (2014-2025)
      • 1.5.2 Lung Cancer
      • 1.5.3 Blood Cancer
      • 1.5.4 Renal Cancer
      • 1.5.5 Bladder Cancer
      • 1.5.6 Melanoma
      • 1.5.7 Hodgkin Lymphoma
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Immune Check Point Inhibitors Market Size
    • 2.2 Immune Check Point Inhibitors Growth Trends by Regions
      • 2.2.1 Immune Check Point Inhibitors Market Size by Regions (2014-2025)
      • 2.2.2 Immune Check Point Inhibitors Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Immune Check Point Inhibitors Market Size by Manufacturers
      • 3.1.1 Global Immune Check Point Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Immune Check Point Inhibitors Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Immune Check Point Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Immune Check Point Inhibitors Key Players Head office and Area Served
    • 3.3 Key Players Immune Check Point Inhibitors Product/Solution/Service
    • 3.4 Date of Enter into Immune Check Point Inhibitors Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Immune Check Point Inhibitors Market Size by Type (2014-2019)
    • 4.2 Global Immune Check Point Inhibitors Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Immune Check Point Inhibitors Market Size (2014-2019)
    • 5.2 Immune Check Point Inhibitors Key Players in United States
    • 5.3 United States Immune Check Point Inhibitors Market Size by Type
    • 5.4 United States Immune Check Point Inhibitors Market Size by Application

    6 Europe

    • 6.1 Europe Immune Check Point Inhibitors Market Size (2014-2019)
    • 6.2 Immune Check Point Inhibitors Key Players in Europe
    • 6.3 Europe Immune Check Point Inhibitors Market Size by Type
    • 6.4 Europe Immune Check Point Inhibitors Market Size by Application

    7 China

    • 7.1 China Immune Check Point Inhibitors Market Size (2014-2019)
    • 7.2 Immune Check Point Inhibitors Key Players in China
    • 7.3 China Immune Check Point Inhibitors Market Size by Type
    • 7.4 China Immune Check Point Inhibitors Market Size by Application

    8 Japan

    • 8.1 Japan Immune Check Point Inhibitors Market Size (2014-2019)
    • 8.2 Immune Check Point Inhibitors Key Players in Japan
    • 8.3 Japan Immune Check Point Inhibitors Market Size by Type
    • 8.4 Japan Immune Check Point Inhibitors Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Immune Check Point Inhibitors Market Size (2014-2019)
    • 9.2 Immune Check Point Inhibitors Key Players in Southeast Asia
    • 9.3 Southeast Asia Immune Check Point Inhibitors Market Size by Type
    • 9.4 Southeast Asia Immune Check Point Inhibitors Market Size by Application

    10 India

    • 10.1 India Immune Check Point Inhibitors Market Size (2014-2019)
    • 10.2 Immune Check Point Inhibitors Key Players in India
    • 10.3 India Immune Check Point Inhibitors Market Size by Type
    • 10.4 India Immune Check Point Inhibitors Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Immune Check Point Inhibitors Market Size (2014-2019)
    • 11.2 Immune Check Point Inhibitors Key Players in Central & South America
    • 11.3 Central & South America Immune Check Point Inhibitors Market Size by Type
    • 11.4 Central & South America Immune Check Point Inhibitors Market Size by Application

    12 International Players Profiles

    • 12.1 Bristol-Myers Squibb Company
      • 12.1.1 Bristol-Myers Squibb Company Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Immune Check Point Inhibitors Introduction
      • 12.1.4 Bristol-Myers Squibb Company Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.1.5 Bristol-Myers Squibb Company Recent Development
    • 12.2 AstraZeneca plc
      • 12.2.1 AstraZeneca plc Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Immune Check Point Inhibitors Introduction
      • 12.2.4 AstraZeneca plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.2.5 AstraZeneca plc Recent Development
    • 12.3 Merck & Co
      • 12.3.1 Merck & Co Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Immune Check Point Inhibitors Introduction
      • 12.3.4 Merck & Co Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.3.5 Merck & Co Recent Development
    • 12.4 Pfizer, Inc
      • 12.4.1 Pfizer, Inc Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Immune Check Point Inhibitors Introduction
      • 12.4.4 Pfizer, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.4.5 Pfizer, Inc Recent Development
    • 12.5 F. Hoffmann-La Roche Ltd
      • 12.5.1 F. Hoffmann-La Roche Ltd Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Immune Check Point Inhibitors Introduction
      • 12.5.4 F. Hoffmann-La Roche Ltd Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.5.5 F. Hoffmann-La Roche Ltd Recent Development
    • 12.6 Incyte Corporation
      • 12.6.1 Incyte Corporation Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Immune Check Point Inhibitors Introduction
      • 12.6.4 Incyte Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.6.5 Incyte Corporation Recent Development
    • 12.7 NewLink Genetics Corporation
      • 12.7.1 NewLink Genetics Corporation Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Immune Check Point Inhibitors Introduction
      • 12.7.4 NewLink Genetics Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.7.5 NewLink Genetics Corporation Recent Development
    • 12.8 Celldex Therapeutics, Inc
      • 12.8.1 Celldex Therapeutics, Inc Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Immune Check Point Inhibitors Introduction
      • 12.8.4 Celldex Therapeutics, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.8.5 Celldex Therapeutics, Inc Recent Development
    • 12.9 GlaxoSmithKline plc
      • 12.9.1 GlaxoSmithKline plc Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Immune Check Point Inhibitors Introduction
      • 12.9.4 GlaxoSmithKline plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.9.5 GlaxoSmithKline plc Recent Development
    • 12.10 Seattle Genetics, Inc.
      • 12.10.1 Seattle Genetics, Inc. Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Immune Check Point Inhibitors Introduction
      • 12.10.4 Seattle Genetics, Inc. Revenue in Immune Check Point Inhibitors Business (2014-2019)
      • 12.10.5 Seattle Genetics, Inc. Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Check point inhibitors are molecules that use the cosmic potential of the immune response system of the body, and its limitless influences to attack the cancer cells present inside the body, as well as avoids relapse of cancer cells. In case any relapse occurs in the body, it can easily be recognized and eliminated by the use of immune memory cells, leaving a healthy tissue.
      Factors such as rise in incidences of cancer and high rate of associated mortality, increased healthcare expenditures, growth in government initiatives to alleviate cancer, and rise in public awareness boost the growth of immune checkpoint inhibitors market.
      In 2018, the global Immune Check Point Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Immune Check Point Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immune Check Point Inhibitors development in United States, Europe and China.

      The key players covered in this study
      Bristol-Myers Squibb Company
      AstraZeneca plc
      Merck & Co
      Pfizer, Inc
      F. Hoffmann-La Roche Ltd
      Incyte Corporation
      NewLink Genetics Corporation
      Celldex Therapeutics, Inc
      GlaxoSmithKline plc
      Seattle Genetics, Inc.

      Market segment by Type, the product can be split into
      CLTA-4 Inhibitors
      PD-1 & PD-L1 Inhibitor

      Market segment by Application, split into
      Lung Cancer
      Blood Cancer
      Renal Cancer
      Bladder Cancer
      Melanoma
      Hodgkin Lymphoma

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Immune Check Point Inhibitors status, future forecast, growth opportunity, key market and key players.
      To present the Immune Check Point Inhibitors development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Immune Check Point Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now